A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

This is the first clinical study with the BMS-986147 compound in healthy subjects. The purpose of this study is to guide the dose range and dose frequency for future studies with BMS-986147 and will provide guidelines for selection of a potentially effective dose in patients.

Key facts

Study ID

NCT02293629

Run by

Bristol-Myers Squibb

People needed

8

Starts

2014-10-01

Expected to finish

2014-11-01

Last updated by the study team

2015-05-19

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men and women, ages 18 to 45 years
• Subjects must not have clinically significant deviation from normal: medical history, physical examination, ECGs and laboratory evaluations
• Women of child bearing potential are eligible for enrollment.
• Women must have a negative pregnancy test

You may not qualify if…

• Evidence of organ dysfunction
• Any significant acute or chronic medical illness
• Inability to: tolerate oral medications, be venipunctured

Where it is running

• Wcct Global, Llc — Cypress, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.